Please use this identifier to cite or link to this item:
|Title:||Liver transplantation for hepatitis B: what is the best hepatitis B immune globulin/antiviral regimen?|
|Authors:||Angus, Peter W;Patterson, Scott J|
|Affiliation:||Victorian Liver Transplant Unit, Austin Health, Heidelberg, Victoria, Australia. email@example.com|
|Citation:||Liver Transplantation : Official Publication of the American Association For the Study of Liver Diseases and the International Liver Transplantation Society; 14 Suppl 2(): S15-22|
|Abstract:||1. Prophylaxis using the combination of lamivudine and high-dose intravenous hepatitis B immunoglobulin (approximately 10,000 IU monthly) reduces the long-term risk of recurrence of hepatitis B in hepatitis B surface antigen-positive transplant recipients to 5% to 10%. However, this therapy is expensive and inconvenient for patients. 2. Recent studies have shown that similar results can be obtained, at far less cost, with much lower doses of intramuscular hepatitis B immune globulin (400-800 IU monthly) in combination with pretransplant and posttransplant lamivudine therapy. 3. The development of lamivudine resistance pre-transplant can lead to hepatic decompensation and increases the risk of posttransplant recurrence in patients receiving hepatitis B immune globulin/lamivudine prophylaxis. Newer nucleos(t)ide analogues with lower resistance rates such as entecavir, adefovir, and tenofovir should therefore replace lamivudine in hepatitis B prophylaxis. 4. Combination therapy with these newer agents and low-dose intramuscular hepatitis B immune globulin is likely to be the most cost effective hepatitis B immune globulin-containing regimen for the prevention of hepatitis B recurrence post-transplant. 5. Some form of hepatitis B virus prophylaxis needs be continued indefinitely post-transplant. However, the use of antivirals with very low rates of drug resistance will make it possible to stop hepatitis B immune globulin therapy in many patients currently receiving hepatitis B immune globulin/nucleos(t)ide combination therapy.|
|Internal ID Number:||18825721|
|Subjects:||Antiviral Agents.administration & dosage|
Drug Therapy, Combination
Hepatitis B.drug therapy.surgery
Immunoglobulins, Intravenous.administration & dosage
Lamivudine.administration & dosage
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.